department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Myleran · pharmadog

pharmadog
drugs
Myleran

drug

patient view →

busulfan

Marketedupdated 2mo ago

by Woodward Pharma Services LLC

Approved

community read0 votes

all catalysts(1)

phase 2 initiation · 1

phase 2 initiation

National Cancer Institute US — busulfan (Phase II Trial Initiation)

News(0)

no news has mentioned this drug yet

brand

Myleran

generic

busulfan

indication

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)

phase

marketed

Data sources

ClinicalTrials.gov

last refreshed 57m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 4

tagApproval8 co-mentions · 4 sources
tagOncology4 co-mentions · 1 sources
companyNational Cancer Institute US1 co-mentions · 1 sources
tagHematology1 co-mentions · 1 sources

Trials studying busulfan

phase3A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)recruitingn=340
phase2Itacitinib for the Prevention of Graft Versus Host Diseaseactive not recruitingn=31
phase2JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosiscompletedn=61
phase2High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegalyrecruitingn=30
phase1Cryopreserved MMUD BM With PTCy for Hematologic Malignancieswithdrawn
phase2Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myelomarecruitingn=40
phase2Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromesrecruitingn=50
phase1Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patientsactive not recruitingn=12

more trials →